Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases
Shots:
- BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform
- As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial milestones, starting with 2 preclinical milestones, plus research support payments & net sales-based royalties
- CUE-501 is a preclinical candidate that targets a B cell-specific membrane protein while engaging virus-specific memory T cells, allowing selective B cell depletion to reduce autoimmune & inflammatory responses
Ref: Globenewswire | Image: Cue Biopharma & Boehringer Ingelheim
Related News:- Boehringer Ingelheim Introduces Vaxxitek HVT+IBD+H5 Vaccine Against Marek’s Disease, Infectious Bursal Disease and H5 Avian Influenza
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
